Cardiotoxicity Market

Market Overview:

The 7 major cardiotoxicity markets reached a value of USD 591.55 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 948.63 Million by 2035, exhibiting a growth rate (CAGR) of 4.37% during 2025-2035.

The cardiotoxicity market has been comprehensively analyzed in IMARC's new report titled "Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Cardiotoxicity is a medical condition that refers to the toxic effects of certain drugs or other substances on the heart muscle and its function. The severity of cardiotoxicity can vary depending on the specific medication or toxin involved, as well as the dose and duration of exposure. Some common symptoms include shortness of breath, chest pain, palpitations, fatigue, weakness, swelling in the legs and ankles, etc. In severe cases, cardiotoxicity can lead to heart failure, which may present as rapid weight gain, difficulty breathing when lying down, and persistent coughing. The diagnosis of cardiotoxicity typically involves a comprehensive evaluation that includes a review of the patient's medical history, a physical examination, and various diagnostic procedures. These tests consist of an electrocardiogram (ECG) to assess heart rhythm abnormalities, an echocardiogram to examine heart function and structure, and a cardiac MRI to determine heart tissue damage. Additionally, blood tests may also be performed to evaluate cardiac enzyme levels and other markers of heart dysfunction. In some cases, a biopsy of heart tissue may be necessary to confirm the diagnosis of cardiotoxicity.

The escalating utilization of chemotherapy drugs, such as anthracyclines, trastuzumab, tyrosine kinase inhibitors, etc., which damage the heart muscle and lead to heart dysfunction, is primarily driving the cardiotoxicity market. In addition to this, the rising prevalence of associated risk factors that contribute to the development of the disease, including long-term use of high-dose NSAIDs, chronic alcohol abuse, illicit drug use, genetic predisposition, etc., is further bolstering the market growth. Moreover, the widespread adoption of several medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, etc., to lower blood pressure, enhance heart function, and reduce fluid buildup in the body is also creating a positive outlook for the market. Besides this, the escalating demand for cardiac rehabilitation programs, which help individuals with cardiotoxicity regain strength and improve cardiovascular function through supervised exercise and other therapies, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of non-invasive imaging tests, such as cardiac MRI, CT angiography, SPECT imaging, etc., on account of their several advantages over more invasive procedures, including reduced risk of complications and early detection of the ailment, is expected to drive the cardiotoxicity market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cardiotoxicity market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cardiotoxicity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cardiotoxicity market in any manner.

Key Highlights:

• Women are substantially more likely to experience cardiotoxicity than men when treated with anthracyclines, and this effect appears to be particularly pronounced when the treatment occurs in childhood.
• The risk of anthracycline-induced cardiotoxicity is greater in prepubertal females, less in premenopausal females, and comparable in postmenopausal females.
• According to a research study, trastuzumab-related cardiotoxicity affected 38% of the elderly (aged ≥68).
• The incidence of cardiotoxicity among anthracyclines ranges between 0.9% and 26%.
• The incidence of cardiotoxicity with 5-FU is roughly 20%.
• Cardiotoxicity has been documented in 7% to 28% of patients on a cyclophosphamide-containing regimen.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cardiotoxicity market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cardiotoxicity market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cardiotoxicity marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cardiotoxicity market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the cardiotoxicity market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the cardiotoxicity market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of cardiotoxicity across the seven major markets?
• What is the number of incident cases (2019-2035) of cardiotoxicity by age across the seven major markets?
• What is the number of incident cases (2019-2035) of cardiotoxicity by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with cardiotoxicity across the seven major markets?
• What is the size of the cardiotoxicity patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of cardiotoxicity?
• What will be the growth rate of patients across the seven major markets?
   

Cardiotoxicity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cardiotoxicity drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cardiotoxicity market?
• What are the key regulatory events related to the cardiotoxicity market?
• What is the structure of clinical trial landscape by status related to the cardiotoxicity market?
• What is the structure of clinical trial landscape by phase related to the cardiotoxicity market?
• What is the structure of clinical trial landscape by route of administration related to the cardiotoxicity market?